Gabather AB (publ) (STO:GABA)

Market Cap	25.96M +1,363.7%
Revenue (ttm)	n/a
Net Income	-4.65M
EPS	-0.02
Shares Out	491.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,877,726
Average Volume	5,892,131
Open	0.0466
Previous Close	0.0468
Day's Range	0.0444 - 0.0550
52-Week Range	0.0230 - 0.1300
Beta	-0.32
RSI	57.23
Earnings Date	May 29, 2026

About Gabather AB

Gabather AB (publ), a pharmaceutical company, develops drug candidates for the treatment of central nervous system diseases. The company offers drugs primarily in the areas of anti-psychotics, anti-depressants and anxiolytics, and analgesics, as well as cognition-enhancing treatments, including Alzheimer’s disease. It focuses on developing GT-002, a pro-cognitive drug candidate for the treatment of Alzheimer’s disease, schizophrenia, and major depressive disorders. The company was incorporated in 2014 and is based in Södertälje, Sweden.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2014
• Employees: 3
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: GABA